<dmn:definitions xmlns:dmn="https://www.omg.org/spec/DMN/20240513/MODEL/" namespace="http://smart.who.int/immunizations" name="DecisionTableIMMZ.D5.DT.JEcontraindications" id="httpsmart.who.intimmunizationsdmnDecisionTableIMMZ.D5.DT.JEcontraindications.dmn">
  <dmn:decision id="DecisionTableIMMZ.D5.DT.JEcontraindications" name="DecisionTableIMMZ.D5.DT.JEcontraindications">
    <dmn:question>Check for contraindications before administering the vaccine(s) due	</dmn:question>
    <dmn:usingTask href="http://smart.who.int/immunizations/bpmn/IMMZ.D5.bpmn#Determine%20vaccine%28s%29%20to%20be%20administered%20based%20on%20contraindications"/>
    <dmn:decisionTable>
      <dmn:input id="input.Potentialcontraindications" label="Potential contraindications"/>
      <dmn:rule id="rule.contra.IMMZ.D5.DT.JEcontraindications.1">
        <dmn:inputEntry>
          <dmn:description>"Potential contraindications" = "Immunocompromised"</dmn:description>
          <dmn:text>The client is immunocomprised</dmn:text>
        </dmn:inputEntry>
        <dmn:outputEntry>
          <dmn:description>"Immunization recommendation status" = "Further evaluation needed"</dmn:description>
          <dmn:text>Clinical judgement is required. Create a clinical note</dmn:text>
        </dmn:outputEntry>
        <dmn:annotationEntry>
          <dmn:text>Inactivated Vero cell-derived vaccines should be used preferentially over live attenuated or live recombinant vaccines in immunocompromised persons. HIV testing is not a prerequisite for vaccination. </dmn:text>
        </dmn:annotationEntry>
        <dmn:annotationEntry>
          <dmn:text> WHO recommendations for routine immunization – summary tables (March 2023) (1)</dmn:text>
        </dmn:annotationEntry>
        <dmn:outputEntry>
          <dmn:description>The client is immunocompromised, consider risks of vaccination and make a judgement. Inactivated Vero cell-derived vaccines are preferred in immunocompromised clients.</dmn:description>
          <dmn:text>The client is immunocompromised, consider risks of vaccination and make a judgement. Inactivated Vero cell-derived vaccines are preferred in immunocompromised clients.</dmn:text>
        </dmn:outputEntry>
        <dmn:annotationEntry>
          <dmn:text>Inactivated Vero cell-derived vaccines should be used preferentially over live attenuated or live recombinant vaccines in immunocompromised persons. HIV testing is not a prerequisite for vaccination. </dmn:text>
        </dmn:annotationEntry>
        <dmn:annotationEntry>
          <dmn:text> WHO recommendations for routine immunization – summary tables (March 2023) (1)</dmn:text>
        </dmn:annotationEntry>
      </dmn:rule>
      <dmn:rule id="rule.contra.IMMZ.D5.DT.JEcontraindications.2">
        <dmn:inputEntry>
          <dmn:description>"Potential contraindications" = "Currently pregnant"</dmn:description>
          <dmn:text>The client is currently pregnant</dmn:text>
        </dmn:inputEntry>
        <dmn:outputEntry>
          <dmn:description>"Immunization recommendation status" = "Further evaluation needed"</dmn:description>
          <dmn:text>Clinical judgement is required. Create a clinical note</dmn:text>
        </dmn:outputEntry>
        <dmn:annotationEntry>
          <dmn:text>If the Japanese encephalitis (JE) risk is sufficient to warrant vaccination of pregnant women, inactivated Vero cell-derived vaccines should be used preferentially over live attenuated or live recombinant vaccines based on the general precautionary principle against using live vaccines in pregnant women, especially if alternative types of vaccines are available. Pregnancy testing is not a prerequisite for JE vaccination. Inadvertent administration of live attenuated or live recombinant JE vaccine to a pregnant woman is not an indication for termination of the pregnancy.</dmn:text>
        </dmn:annotationEntry>
        <dmn:outputEntry>
          <dmn:description>The client is currently pregnant, consider risks of vaccination and make a judgement. Inactivated Vero cell-derived vaccines are preferred over live attenuated or live recombinant vaccines.</dmn:description>
          <dmn:text>The client is currently pregnant, consider risks of vaccination and make a judgement. Inactivated Vero cell-derived vaccines are preferred over live attenuated or live recombinant vaccines.</dmn:text>
        </dmn:outputEntry>
        <dmn:annotationEntry>
          <dmn:text>If the Japanese encephalitis (JE) risk is sufficient to warrant vaccination of pregnant women, inactivated Vero cell-derived vaccines should be used preferentially over live attenuated or live recombinant vaccines based on the general precautionary principle against using live vaccines in pregnant women, especially if alternative types of vaccines are available. Pregnancy testing is not a prerequisite for JE vaccination. Inadvertent administration of live attenuated or live recombinant JE vaccine to a pregnant woman is not an indication for termination of the pregnancy.</dmn:text>
        </dmn:annotationEntry>
      </dmn:rule>
    </dmn:decisionTable>
  </dmn:decision>
</dmn:definitions>